San Francisco startup Composition Therapeutics is additionally working on an oral, once-daily GLP-1 drug termed GSBR-1290—the drug surpassed Wall Avenue’s expectations in June when a mid-phase research confirmed average weight loss of all around 6% and it ideas to get started on Yet another mid-phase trial towards the end of the 12 months—tha

San Diego-dependent Viking Therapeutics marked itself as a serious competitor during the weight loss drug current market in February soon after revealing promising data from the mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when provided to be a weekly injection As well as in March t